Ajulemic acid
From Wikipedia, the free encyclopedia
Ajulemic acid
|
|
Systematic (IUPAC) name | |
(6aR,10aR) 3-(1,1-dimethylheptyl)-6a,7,10,10a-tetrahydro-1-hydroxy-6,6-dimethyl- 6H-Dibenzo(b,d)pyran-9-carboxylic acid | |
Identifiers | |
CAS number | |
ATC code | ? |
PubChem | |
Chemical data | |
Formula | C25H36O4 |
Mol. mass | 400.551 g/mol |
Pharmacokinetic data | |
Bioavailability | ? |
Metabolism | ? |
Half life | ? |
Excretion | ? |
Therapeutic considerations | |
Pregnancy cat. |
? |
Legal status | |
Routes | ? |
Ajulemic acid (IP-751) is a synthetic cannabinoid derivative of the non-psychoactive THC metabolite 11-nor-9-carboxy-THC which shows useful analgesic and anti-inflammatory effects without causing a subjective "high".[1] It is being developed for the treatment of neuropathic pain and inflammatory conditions such as arthritis.[2] It does not however share the anti-emetic effects of other cannabinoids but may be useful for treating pain and chronic inflammatory conditions where nausea is not present.[3] Side effects include dry mouth, tiredness and dizziness. The mechanism of action has not yet been established, but ajulemic acid may activate the CB1 receptor in a different way to psychoactive cannabinoids. [4]
[edit] References
- ^ Burstein SH, Karst M, Schneider U, Zurier RB (2004). "Ajulemic acid: A novel cannabinoid produces analgesia without a "high"". Life Sci. 75 (12): 1513–22. doi: . PMID 15240185.
- ^ Mitchell VA, Aslan S, Safaei R, Vaughan CW (2005). "Effect of the cannabinoid ajulemic acid on rat models of neuropathic and inflammatory pain". Neurosci. Lett. 382 (3): 231–5. doi: . PMID 15925096.
- ^ Burstein S (2005). "Ajulemic acid (IP-751): synthesis, proof of principle, toxicity studies, and clinical trials". AAPS J 7 (1): E143–8. doi: . PMID 16146336.
- ^ Vann RE, Cook CD, Martin BR, Wiley JL (2007). "Cannabimimetic properties of ajulemic acid". J. Pharmacol. Exp. Ther. 320 (2): 678–86. doi: . PMID 17105826.
|